IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Pharmaceuticals: Top Five Third Level Therapeutic Classes
ATC Therapeutic
Class
Description
US
Dollar
Sales
(‘000s)
Share of
Worldwide
Corporate Sales
%
Percentage
Growth Sep
07/Sep 08
USD USD FIXED
RATE
TOTAL SALES 13722422 100.0 10 5
1 A10B ORAL ANTIDIABETICS 4576045 33.3 14 11
2 A2B ANTIULCERANTS 4550938 33.2 -1 -3
3 C9C ANGIOTEN-II ANTAG, PLAIN 1506973 11.0 17 6
4 L2A CYTOSTATIC HORMONES 789109 5.8 12 1
5 L1X ALL OTH. ANTINEOPLASTICS 344256 2.5 39 39
This ta ble shows the com pany’s top five third level ther a peu tic classes. Sales data cov ers the twelve
month pe riod to Sep tem ber 2008. Sta tis tics for third-level ther a peu tic class share of cor po rate rev e nue,
US dol lar and US dol lar fixed rate growth over the pre vi ous twelve month pe riod are presented.
The lead ing five ther a peu tic classes ac count for 85.8% of cor po rate rev e nue.
Pharmaceuticals: Leading International Products
International
Products
Share of
Worldwide
Corporate Sales
%
Percentage
Growth Sep
07/Sep 08
USD USD FIXED
RATE
TOTAL SALES 100.0 10 5
1 TAKEPRON 32.1 -1 -3
2 ACTOS 26.7 12 10
3 BLOPRESS 11.0 17 6
4 ENANTONE 6.3 13 1
5 BASEN 3.1 3 -6
6 ACTOPLUS MET 3.0 56 55
7 VELCADE 2.5 40 40
8 AMITIZA 1.4 66 66
9 BLOPRESS COMP 1.3 20 7
10 PREVPAC 1.0 -0 -1
This ta ble shows the com pany’s lead ing ten phar ma ceu ti cal prod ucts. For each prod uct, its per cent age
share of cor po rate rev e nue and US dol lar and US dol lar fixed rate growth are shown. In this study, in ter -
na tional prod ucts are used. The con cept of the in ter na tional prod uct was de vised for IMS’s in ter na tional
da ta base MI DAS, to en able us ers to eval u ate sales of a prod uct in ter na tion ally, even if the prod uct is
known by dif fer ent names in dif fer ent coun tries. Prod ucts are linked in ter na tion ally if at least two of the
fol low ing three char ac ter is tics are the same as in coun try of first launch: brand name; marketing
corporation; active ingredients.
The top ten in ter na tional prod ucts ac counted for 88.4% of cor po rate rev e nue.
© 2009 IMS Health In cor po rated or its af fil i ates Page 87